<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018286</url>
  </required_header>
  <id_info>
    <org_study_id>TA799-012</org_study_id>
    <nct_id>NCT05018286</nct_id>
  </id_info>
  <brief_title>Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.</brief_title>
  <acronym>STARS extend</acronym>
  <official_title>An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VectivBio AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VectivBio AG</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to assess long-term safety and tolerability of&#xD;
      apraglutide in subjects with SBS-IF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicenter, open label extension trial to collect further safety,&#xD;
      tolerability, efficacy, durability, and clinical outcomes of apraglutide once weekly&#xD;
      adminstration, for up to an additional 104 weeks. Eligible subjects would be those who have&#xD;
      successfully completed TA799-007 or TA799-013 trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>System organ class, frequency and severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical chemistry</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Clinical Chemistry panel of analytes will be examined for clinically significant changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Hematology panel of analytes will be examined for clinically significant changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Hemostasis INR will be examined for clinically significant changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Urinanalysis panel of analytes will be examined for clinically significant changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinically relevant changes in vital signs</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Systolic and diastolic blood pressure in mmHg will be examined for clinically significant changes.&#xD;
Heart rate in Beats per Minute (BPM) will be examined for clinically significant changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinically relevant changes in electrocardiogram</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>ECG; intervals and rhythm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PS volume</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PS frequency</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Change in PS days/week from baseline to week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in PS total energy</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Units: kcal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PS infusion time</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reaching enteral autonomy</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>From baseline to week 104</time_frame>
    <description>Units: kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the Patient Global Impression of Severity (PGIS)</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the Pittsburgh Sleep Quality Inventory (PSQI)</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the Patient Global Impression of Change (PGIC)</measure>
    <time_frame>From baseline to week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Apraglutide subcutaneous (SC) injections, once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptide analogue of Glucagon-like Peptide 2 (GLP-2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apraglutide</intervention_name>
    <description>Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2</description>
    <arm_group_label>Apraglutide subcutaneous (SC) injections, once weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females with a diagnosis of SBS-IF secondary to surgical resection of the&#xD;
             small intestine, with Colon-in-Continuity (CIC) or stoma, who have completed parent&#xD;
             trials TA799-007 or TA799-013&#xD;
&#xD;
          2. Able to give informed consent and agree to follow the details of participation as&#xD;
             outlined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject not capable of understanding or not willing to adhere to the trial visit&#xD;
             schedules and other protocol requirements.&#xD;
&#xD;
          2. Any other reason judged not eligible by the Investigator.&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seabrook</last_name>
    <role>Study Director</role>
    <affiliation>VectivBio AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eremeeva</last_name>
    <phone>+41615513030</phone>
    <email>clinicaltrials@vectivbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short Bowel Syndrome</keyword>
  <keyword>SBS</keyword>
  <keyword>Intestinal Failure</keyword>
  <keyword>SBS-IF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

